Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Edge to help fund EG1962 development through $10mm in Hercules debt; loan restated for up to additional $20mm

Executive Summary

Hercules Technology Growth Capital agreed to provide Edge Therapeutics Inc. (targeted drug delivery) with up to $10mm in venture debt financing, $3mm of which the biotech drew down up front. The remaining $7mm is available upon reaching milestones. The secured notes have a four-year term, and Edge is required to pay back interest only for the first 12 months, following by 30 equal monthly payments of principal plus interest.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Site Specific
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement
    • Nonconvertible Debt

Related Companies